Methoxy polyethylene glycol-epoetin beta: new drug. Pegylated epoetin beta: risk of cardiovascular disorders.
No tangible benefit, but a risk of cardiovascular adverse effects due to haemogloblin levels that are frequently too high compared with other epoetins.